



Medicure Inc. Investor Presentation

MPH:TSXV



Forward Looking Statement

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for Medicure Inc., business and operational results. By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, product recalls, competition from similar products and other factors including those risks and uncertainties identified above, and those contained in the Company's most recent MD&A and Form 20F.

Medicure Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

Why Invest in Medicure

Medicure is a profitable R&D specialty pharmaceutical company focused on the US market with an E-commerce pharmacy

Profitable and growing profit

Steady sales of AGGRASTAT


Growing sales of ZYPITAMAG

Marley Drug e-Commerce pharmacy Subsidiary


MC-1: priority review voucher upon completion of phase 3 trial of 10 PNPO patients

No debt

Progress and Profitability




Net Revenue



Adjusted EBITDA

2022 EPS: \$0.13



Net Income (Loss)

Medicure's Leadership Team



Albert D. Friesen
*Chief Executive Officer &
Chairman of the Board*

- Founded Medicure in 1997
- Created and developed multiple companies, including ABI Biotechnology (Apotex Fermentation), The Winnipeg Rh Institute, DiaMedica and Genesys Venture Inc.



Neil Owens
*President &
Chief Operating Officer*

- President & COO since 2019
- Joined Medicure in 2014 in Medical Affairs
- PhD in Organic Chemistry
- Responsible for the execution of strategic plans and oversight of operations



Reuben Saba
*Vice President,
Medical and Business Affairs*

- VP since 2019
- Joined Medicure in 2014 in Medical Affairs
- PhD in Neurobiology
- Responsible for the development of new business opportunities



Haaris Uddin
Chief Financial Officer

- Joined Medicure in 2022 as CFO
- Responsible for financial reporting activities and oversight of finance systems and strategy

AGGR[^]STAT[®]

(tirofiban hydrochloride) Injection

\$11.7M

In 2022

↑1.3%

from the prior year

\$25M

GPIIb/IIIa market*

INDICATION

Acute Coronary Syndrome

PRODUCT HIGHLIGHTS

- Leading IV antiplatelet in its class
- Medicure grew market share from 2% to 65%
- Used in more than 1,200 hospitals
- Three formats of the product available

LEARN MORE AT
Aggrastat.com



Zypitamag[®]

(pitavastatin) tablets

\$3.6M

In 2022

↑12%

from the prior year

\$4B

US Statin market*

INDICATION

High Cholesterol

PRODUCT HIGHLIGHTS

- Improvements over older statins
- Low rates of side effects like muscle pain
- Doesn't interact with other medications
- Once daily low dose with strong LDL reduction

LEARN MORE AT
Zypitamag.com




ZYPITAMAG Customer Quotes

WATCH OUR
TV Commercial



“Zypitamag is a great option. It's nice to be able to skip the "pain" of step therapy and prior authorization hassles for patients who really need a statin with low rates of muscle pain.

Dr. Kimberly Rieniets



“The results are back after 2 months on Zypitamag. Wow!

My numbers have come way down, and I am so happy with the results!

Richard H.



“Zypitamag just works for me. And, it's affordable. I don't even use my insurance coverage as your company discount is better.

Diana



“I personally tried multiple statins and had intolerable side effects. Because Zypitamag is metabolized differently, it's a statin I can take!

Robert P., MD

These are stock photos representing actual testimonials. Personal experiences with ZYPITAMAG may differ.



Medicare's Pharmacy Subsidiary and E-Commerce Platform

\$7.8M

In 2022

↑12%

from the prior year

\$5.7B

US Online pharmacy
market*

WHAT IS MARLEY DRUG

- A US pharmacy subsidiary licensed to ship FDA approved medications to all 50 states
- Facilitates Medicare selling ZYPITAMAG directly to consumers

HIGHLIGHTS

- More than 100,000 customers
- Increased ZYPITAMAG units dispensed by 253% vs 2021
- Also sells most generic and branded medications
- E-commerce website for easy ordering and refills

LEARN MORE AT
MarleyDrug.com



Marley Drug Customer Quotes

SEE OUR TV AD FEATURING
A Real Customer Quote



I really love Marley's quick responses and the fact that I can purchase a 6-month supply. The staff is wonderful, helpful and knowledgeable.

Patty S.



The Wholesale Price List made my prescription easy to afford. My monthly cost with insurance was almost \$150! Now I can get a 6-month supply for only \$37.

Mark T.



As soon as my doctor submitted the prescription, I was contacted by Terri, who explained the process and set up delivery to my home. It could not have been easier!

Amy W.



Check out this pharmacy. My cardiologist referred me to them for best price on cholesterol lowering med. I found them to be helpful, professional and provide prompt service.

Theresa S.

Why Did Medicure Acquire Marley Drug

- A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug
- A marketing vehicle for other branded drugs
- Saves on high fees to wholesalers and pharmacy benefit managers



Watch our explainer video here

PHASE 3 CLINICAL STUDY

Development of MC-1 for Rare Pediatric Disease

Phase 3 study for treatment of rare pediatric disease called PNPO deficiency

- Study involves 10-15 patients in US and Australia
- Orphan drug status
- If approved Medicare is eligible for a priority review voucher, which can be redeemed or sold
- **\$100-200 million potential**
- Medicare has significant experience with MC-1 through exploration of other clinical applications



Medicure's Growth Strategy

Medicure plans to use its profit to fund R&D and acquisitions

Medicure is profitable through AGGRASTAT, ZYPITAMAG and Marley Drug

Funding R&D of MC-1 and beyond

Exploring acquisition opportunities of other pharmaceutical products and to build the Marley Drug business

5 Key Takeaways About Medicure

1. Medicure's focus is on pharmaceuticals and healthcare products for the US market
2. Proven success with AGGRASTAT, building sales of ZYPITAMAG
3. Focus on direct consumer sales for growth and profitability through Marley Drug pharmacy subsidiary
4. R&D focus on MC-1 for rare orphan disease
5. We believe in growth through innovation and service



Watch our 25th anniversary video here



Thank You for Your Interest

For Further Information

Visit our Websites

Medicure.com

AGGRASTAT.com

ZYPITAMAG.com

Marley Drug.com

Investor Relations

ir@medicure.com

1-888-435-2220 (Ext. 228)

Follow us on [LinkedIn](#)